Stocks to sell

In any other circumstance, Opendoor Technologies (NASDAQ:OPEN) stock may have been a no-brainer investment. Source: PREMIO STOCK/Shutterstock.com As you probably know, owning real estate is the epitome of the American Dream — but the paperwork to seal the deal is a veritable nightmare. Opendoor’s digitalization of the buying and selling process is the answer we’ve
Small biotech companies such as Denmark’s Orphazyme (NASDAQ:ORPH) usually have one major product, which pushes them into the spotlight. For ORPH stock, that one product is Arimoclomol. Source: Iryna Imago / Shutterstock.com Arimoclomol is a drug that could treat the rare progressive genetic disorder called Niemann-Pick Disease Type C (NPC). Investors looking for a breakthrough
The timing of DiDi Global’s (NYSE:DIDI) initial public offering could not have been any better. Insiders and early investors probably knew about the Chinese regulatory crackdown days after its IPO. They lost the least after DIDI stock plunged. Speculators who bought the stock are in for a rough ride next. Source: Piotr Swat / Shutterstock.com
Nio (NYSE:NIO) has had one of the most incredible turnarounds in recent memory. The company’s initial public offering (IPO) was priced at $6 per share, and NIO stock stayed in the single digits following the IPO. Source: Sundry Photography / Shutterstock.com While Nio made a decent case about being able to beat Tesla (NASDAQ:TSLA) in